Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Mol Neurobiol ; 55(8): 7062-7071, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-29383685

RESUMEN

Several pieces of evidence indicate that elastase-2 (ELA2; chymotrypsin-like ELA2) is an alternative pathway to the generation of angiotensin II (ANGII). Elastase-2 knockout mice (ELA2KO) exhibit alterations in the arterial blood pressure and heart rate. However, there is no data on the behavioral consequences of ELA2 deletion. In this study, we addressed this question, submitting ELA2KO and wild-type (WT) mice to several models sensitive to anxiety- and depression-like, memory, and repetitive behaviors. Our data indicates a higher incidence of barbering behavior in ELA2KO compared to WT, as well as an anxiogenic phenotype, evaluated in the elevated plus maze (EPM). While a decrease in locomotor activity was observed in ELA2KO in EPM, this feature was not the main source of variation in the other parameters analyzed. The marble-burying test (MBT) indicated increase in repetitive behavior, observed by a higher number of buried marbles. The actimeter test indicated a decrease in total activity and confirmed the increase in repetitive behavior. The spatial memory was tested by repeated exposure to the actimeter in a 24-h interval. Both ELA2KO and WT exhibited decreased activity compared to the first exposure, without any distinction between the genotypes. However, when submitted to the cued fear conditioning, ELA2KO displayed lower levels of freezing behavior in the extinction session when compared to WT, but no difference was observed during the conditioning phase. Increased levels of BDNF were found in the prefrontal cortex but not in the hippocampus of ELA2KO mice compared to WT. Finally, in silico analysis indicates that ELA2 is putatively able to cleave BDNF, and incubation of the purified enzyme with BDNF led to the degradation of the latter. Our data suggested an anxiogenic- and antidepressant-like phenotype of ELA2KO, possibly associated with increased levels of BDNF in the prefrontal cortex.


Asunto(s)
Antidepresivos/metabolismo , Ansiedad/enzimología , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Corteza Prefrontal/metabolismo , Serina Endopeptidasas/deficiencia , Animales , Conducta Animal , Simulación por Computador , Condicionamiento Psicológico , Miedo , Femenino , Masculino , Ratones Endogámicos C57BL , Ratones Noqueados , Fenotipo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Proteínas Recombinantes/farmacología , Serina Endopeptidasas/genética , Serina Endopeptidasas/metabolismo
2.
Eur Neuropsychopharmacol ; 17(11): 735-42, 2007 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17462866

RESUMEN

The present study was designed to assess the effect of dexamethasone, a synthetic glucocorticoid receptor agonist, in the sucrose preference test in rats. Rats treated acutely with dexamethasone (5-10 mg/kg) showed a significant decrease in sucrose preference (anhedonia) in comparison to vehicle treated rats, although 1 mg/kg dexamethasone did not alter the sucrose preference. Daily paroxetine treatment (10 g/kg, i.p., 14 days) reversed the anhedonic effect of acute dexamethasone (5 mg/kg), while causing no increased sucrose preference in rats that received dexamethasone vehicle. The paroxetine vehicle treated rats showed anhedonia even 14 days after acute dexamethasone administration. Paroxetine (10 mk/kg, i.p. for 28 days) also reversed anhedonia induced by chronic mild stress (8 weeks). In conclusion, acute dexamethasone induced an enduring anhedonic state that was reversed by repeated paroxetine treatment. Thus, the present study adds new data to the evidence supporting an important role for glucocorticoid in depression.


Asunto(s)
Antidepresivos de Segunda Generación/administración & dosificación , Depresión/tratamiento farmacológico , Depresión/etiología , Dexametasona/toxicidad , Glucocorticoides/toxicidad , Paroxetina/administración & dosificación , Estrés Psicológico/complicaciones , Análisis de Varianza , Animales , Conducta Animal/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Interacciones Farmacológicas , Preferencias Alimentarias/efectos de los fármacos , Masculino , Ratas , Ratas Wistar , Factores de Tiempo
3.
Braz J Med Biol Res ; 45(4): 357-65, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22392189

RESUMEN

This paper presents an up-to-date review of the evidence indicating that atypical neurotransmitters such as nitric oxide (NO) and endocannabinoids (eCBs) play an important role in the regulation of aversive responses in the periaqueductal gray (PAG). Among the results supporting this role, several studies have shown that inhibitors of neuronal NO synthase or cannabinoid receptor type 1 (CB1) receptor agonists cause clear anxiolytic responses when injected into this region. The nitrergic and eCB systems can regulate the activity of classical neurotransmitters such as glutamate and γ-aminobutyric acid (GABA) that control PAG activity. We propose that they exert a 'fine-tuning' regulatory control of defensive responses in this area. This control, however, is probably complex, which may explain the usually bell-shaped dose-response curves observed with drugs that act on NO- or CB1-mediated neurotransmission. Even if the mechanisms responsible for this complex interaction are still poorly understood, they are beginning to be recognized. For example, activation of transient receptor potential vanilloid type-1 channel (TRPV1) receptors by anandamide seems to counteract the anxiolytic effects induced by CB1 receptor activation caused by this compound. Further studies, however, are needed to identify other mechanisms responsible for this fine-tuning effect.


Asunto(s)
Ansiedad/fisiopatología , Reacción de Fuga/fisiología , Neurotransmisores/fisiología , Sustancia Gris Periacueductal/fisiología , Transmisión Sináptica/fisiología , Animales , Ansiedad/metabolismo , Ácidos Araquidónicos/farmacología , Agonistas de Receptores de Cannabinoides/farmacología , Endocannabinoides/farmacología , Endocannabinoides/fisiología , Ratones , Óxido Nítrico/fisiología , Sustancia Gris Periacueductal/metabolismo , Alcamidas Poliinsaturadas/farmacología , Ratas , Canales Catiónicos TRPV/fisiología
4.
Braz. j. med. biol. res ; 45(4): 357-365, Apr. 2012. tab
Artículo en Inglés | LILACS | ID: lil-622757

RESUMEN

This paper presents an up-to-date review of the evidence indicating that atypical neurotransmitters such as nitric oxide (NO) and endocannabinoids (eCBs) play an important role in the regulation of aversive responses in the periaqueductal gray (PAG). Among the results supporting this role, several studies have shown that inhibitors of neuronal NO synthase or cannabinoid receptor type 1 (CB1) receptor agonists cause clear anxiolytic responses when injected into this region. The nitrergic and eCB systems can regulate the activity of classical neurotransmitters such as glutamate and γ-aminobutyric acid (GABA) that control PAG activity. We propose that they exert a ‘fine-tuning’ regulatory control of defensive responses in this area. This control, however, is probably complex, which may explain the usually bell-shaped dose-response curves observed with drugs that act on NO- or CB1-mediated neurotransmission. Even if the mechanisms responsible for this complex interaction are still poorly understood, they are beginning to be recognized. For example, activation of transient receptor potential vanilloid type-1 channel (TRPV1) receptors by anandamide seems to counteract the anxiolytic effects induced by CB1 receptor activation caused by this compound. Further studies, however, are needed to identify other mechanisms responsible for this fine-tuning effect.


Asunto(s)
Animales , Ratones , Ratas , Ansiedad/fisiopatología , Reacción de Fuga/fisiología , Neurotransmisores/fisiología , Sustancia Gris Periacueductal/fisiología , Transmisión Sináptica/fisiología , Ansiedad/metabolismo , Ácidos Araquidónicos/farmacología , Agonistas de Receptores de Cannabinoides/farmacología , Endocannabinoides/farmacología , Endocannabinoides/fisiología , Óxido Nítrico/fisiología , Sustancia Gris Periacueductal/metabolismo , Alcamidas Poliinsaturadas/farmacología , Canales Catiónicos TRPV/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA